Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9550 and AZD6234 in Overweight and Obesity (CONTEMPO)
NCT06151964Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Primary completion
- Jan 2027
- Modality
- Peptides, Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of AZD9550 in obesity, type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Sep 2023; status: active, not recruiting.
02
Drugs
AZD9550
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06151964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06151964.